ZYN gets FDA modified-risk orders for 20 pouches (2026)

What the FDA decision means for ZYN

Philip Morris International Inc. (PMI) said the US Food and Drug Administration has issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of its ZYN nicotine pouch products. The authorizations let PMI market specific reduced-risk information compared with cigarettes. According to the company, it is the first time the FDA has granted modified-risk authorization for a nicotine pouch product. The decision applies to 20 ZYN products covering multiple flavours and two nicotine strengths per flavour. The MRTP orders are effective immediately, based on the information shared by PMI and the FDA.

The exact modified-risk claim PMI can use

PMI said the FDA’s MRTP orders allow the company to market a specific claim for the authorized ZYN products. The claim is: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” PMI also framed the authorization as allowing it to communicate that switching completely from cigarettes to ZYN lowers the risk of several smoking-related diseases. The FDA’s granted order text cited in the release states the products satisfied requirements under section 911(g)(1)(A) and (B). The FDA text also notes its determination considered how products are actually used by consumers and the potential population-level impact, including people who do not currently use tobacco products.

Products covered: 20 ZYN variants across flavours and strengths

The MRTP orders cover 10 flavours, each in 3 mg and 6 mg nicotine strengths, totalling 20 SKUs. These include Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen. PMI’s list also includes the same flavours and strengths and specifies “Cool Mint,” “Peppermint,” “Spearmint,” and “Wintergreen,” among others. The FDA described nicotine pouches as small fiber pouches containing nicotine designed to be placed between a person’s gum and lip.

How this differs from the January 2025 authorization

The FDA had previously authorized the same 20 ZYN products for sale in the United States through the Premarket Tobacco Product Application (PMTA) pathway on January 16, 2025, following scientific review. However, that earlier PMTA authorization did not allow Swedish Match, the PMI subsidiary that makes ZYN, to market the products as reducing disease risk. The June 2026 MRTP orders go further by allowing a specific modified-risk claim tied to multiple major smoking-related diseases. In other words, the products were already authorized to be sold, but the scope of permitted marketing statements has now expanded for these 20 variants.

Timeline: from applications to public comments to final orders

The review process included formal steps that unfolded over more than a year. The FDA established a docket for public comment on June 18, 2025, on regulations.gov under docket number FDA-2025-N-0835. The comment period closed on March 4, 2026 at 11:59 p.m. ET. Separately, the FDA posted a final set of materials related to Swedish Match USA’s MRTP applications on February 2 (year not specified in the provided text), which was described as moving the long-running process into its closing phase. The FDA also issued a Federal Register notice announcing a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting on January 22, 2026 to discuss MRTP applications for ZYN nicotine pouch products.

Company context: Swedish Match and PMI’s reduced-risk portfolio

PMI said the MRTP authorization underscores its position in reduced-risk tobacco and nicotine products, noting it holds MRTP authorizations for ZYN, versions of IQOS devices and consumables, and eight General snus products. The company also reiterated that ZYN was the first nicotine pouch authorized for sale in the US in January 2025 after what it described as a rigorous scientific review. The latest FDA decision adds a new layer of authorization: not just marketing permission, but permission to state specific reduced-risk information compared with cigarettes.

What the FDA said about consumer information

A separate report on the decision cited Bret Koplow, acting director of the FDA’s Center for Tobacco Products, on the role of modified-risk reviews. The statement described FDA review as intended to ensure adult users have clear, science-based information about the relative harms of tobacco products so they can make informed choices. It also said the decision allows these products to be marketed with a modified-risk claim that informs adults who smoke about the lower risks associated with these products. The FDA’s granted order language cited by PMI similarly emphasised both individual harm reduction and broader public health considerations.

Market and regulatory significance of a first-of-its-kind MRTP pouch order

The main significance is regulatory: ZYN becomes the first nicotine pouch category product to receive MRTP orders authorizing reduced-risk claims versus cigarettes, based on the information provided. For PMI, the authorization expands what can be said in marketing for these specific SKUs, which can shape how the products are positioned relative to cigarettes. The decision is limited to the 20 authorised variants and the specific claim language permitted under the MRTP orders. It does not apply to other nicotine pouch brands or unlisted ZYN variants.

Key points for investors and consumers to track

Investors typically watch how regulatory permissions affect a company’s ability to communicate product attributes, especially in categories positioned as alternatives to combustible cigarettes. Here, the FDA allowed explicit reduced-risk statements tied to named diseases when using ZYN instead of cigarettes, which is a step beyond standard product authorisation. Consumers and public health stakeholders may focus on how the claim is presented, the emphasis on switching from cigarettes, and the FDA’s requirement that claims meet legal and scientific standards. Future updates, if any, would likely relate to how the products are marketed under the MRTP conditions and whether similar authorizations expand to other products or categories.

Conclusion

The FDA’s June 30, 2026 MRTP orders give PMI permission to market 20 ZYN nicotine pouch variants with a specific modified-risk claim versus cigarettes, making ZYN the first nicotine pouch product with such authorization. The products were already cleared for sale in January 2025, but the new orders allow defined reduced-risk messaging tied to major smoking-related diseases. The authorizations are effective immediately and apply only to the listed flavours and 3 mg and 6 mg strengths. The next developments to watch are any further FDA actions on modified-risk claims in the nicotine pouch category and how PMI implements the permitted claim for the authorised ZYN products.